AU Patent

AU2024265078A1 — Combination therapy for a ras related disease or disorder

Assigned to Revolution Medicines Inc · Expires 2025-12-11 · 0y expired

What this patent protects

The present disclosure relates to combination therapies for treating a RAS related disease or disorder (e.g., cancer). In particular, the present disclosure relates to methods of treating a RAS related disease or disorder in a subject in need thereof, comprising administering to …

USPTO Abstract

The present disclosure relates to combination therapies for treating a RAS related disease or disorder (e.g., cancer). In particular, the present disclosure relates to methods of treating a RAS related disease or disorder in a subject in need thereof, comprising administering to the subject a therapeutically effective amount of a RAS(ON) inhibitor in combination with one or more additional therapeutic agents, pharmaceutical compositions comprising a therapeutically effective amounts of the same, kits comprising the compositions and methods of use therefor.

Drugs covered by this patent

Patent Metadata

Patent number
AU2024265078A1
Jurisdiction
AU
Classification
—
Expires
2025-12-11
Drug substance claim
No
Drug product claim
No
Assignee
Revolution Medicines Inc
Source
FDA Orange Book + USPTO grounding via Google Patents

Bibliographic data sourced from FDA Orange Book + USPTO public records. Plain-English summary generated by AI grounded in source text. Patent term extensions (PTR, SPC, pediatric) may shift the effective expiry. Not legal advice.

Track this patent

Get a daily-checked alert when vulnerability score, expiry, classification, or assignee changes. Email, Slack, or Teams delivery. Pro: 50 watches, Free: 3.